pharmaphorum

NOVEMBER 7, 2022

As we continue to enter new markets, grow within our existing markets and reach a broader population, we continue to invest in our operations, talent and technology capabilities to support that growth.” ” Jill Howe, Lineage Cell Therapeutics. ” Patrick Genestin, 1910 Genetics .

Pharmaceutical Companies 103

Pharmaceutical Companies Pharmaceutical Companies 103

European Pharmaceutical Review

NOVEMBER 11, 2022

The American Heart Association (AHA)’s Scientific Sessions 2022 is a global exchange of the latest advancements in research and clinical practice of cardiovascular science. Heart failure treated with first-in-human in vivo gene-editing therapy using CRISPR technology . Baxdrostat – treating hypertension drug-resistance.

Labelling 100

Labelling Hospitals 100

Pharmaceutical Technology

NOVEMBER 15, 2022

However, a recent study in the Journal of American Medical Association suggests that Paxlovid may not be the sole cause for this relapse in Covid-19 symptoms. In the recent JAMA publication, Covid-19 symptoms were assessed for 29 days in untreated participants who received a placebo in the ACTIV-2/A5401 trial between August and November 2020.

Vaccines 64

Vaccines Documentation 64

Putting Patients First Blog

JANUARY 10, 2024

Open Enrollment Periods: The NHC supports the amendment for a standardized open enrollment period across State Exchanges from November 1 to at least January 15, allowing more time for consumers to make informed health coverage decisions, access assistance, reducing confusion, facilitating easier health coverage comparisons and transitions.

Insurance Coverage and Processing 40

Insurance Coverage and Processing Communication Documentation Diabetes 40